Menu Search
Equities

Devyser Diagnostics AB

OL0:DEU

Devyser Diagnostics AB

Actions
  • Price (EUR)11.20
  • Today's Change-0.65 / -5.49%
  • Shares traded0.00
  • 1 Year change+123.11%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Devyser Diagnostics AB had net income fall 16.64% from a loss of 45.95m to a larger loss of 53.60m despite revenues that grew 33.71% from 126.61m to 169.30m over the same period.
Gross margin80.00%
Net profit margin-36.11%
Operating margin-39.14%
Return on assets-14.51%
Return on equity-19.11%
Return on investment-16.40%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Devyser Diagnostics AB fell by 100.70m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 69.70m for operations while cash used for investing totalled 32.00m.
Cash flow per share-2.86
Price/Cash flow per share--
Book value per share21.17
Tangible book value per share16.14
More ▼

Balance sheet in SEKView more

Devyser Diagnostics AB appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio4.21
Quick ratio3.81
Total debt/total equity0.1754
Total debt/total capital0.1492
More ▼

Growth rates in SEK

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-22.65
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.